Shares of Dendreon Corp. (NASDAQ:DNDN) inched up after the European Commission granted marketing authorization in the European Union (EU) for Provenge (sipuleucel-T) in asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC) in men for whom chemotherapy is not yet indicated.